AIM
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E N/A, PEG 0.71, P/S 48.15
- Price/Sales ratio of 48.15 is extreme for a shrinking company
- Negative Price/Book ratio
- No Graham Number available due to lack of earnings/assets
Ref Revenue Growth -53.30%
- EPS surprises are positive
- Revenue growth is deeply negative (-53.3%)
- Operating margins are unsustainable
Ref Historical Price Performance
- 5-year return of -99.8%
- 1-year return of -86.6%
Ref Piotroski F-Score, Current Ratio
- Piotroski F-Score 1/9
- Current Ratio 0.53 indicates inability to cover short-term liabilities
Ref Dividend Yield N/A
- No dividend paid
- Zero payout capacity
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AIM and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AIM
AIM ImmunoTech Inc.
Primary
|
-99.8% | -99.0% | -86.6% | -79.0% | -46.4% | -7.1% |
|
JAGX
Jaguar Health, Inc.
Peer
|
-100.0% | -100.0% | -92.8% | -82.2% | -34.7% | -7.8% |
|
ISPC
iSpecimen Inc.
Peer
|
-99.9% | -99.5% | -89.9% | -85.3% | -46.7% | -9.9% |
|
SXTP
60 Degrees Pharmaceuticals, Inc.
Peer
|
-99.8% | -99.8% | -85.4% | -69.3% | -5.6% | -5.2% |
|
INBS
Intelligent Bio Solutions Inc.
Peer
|
-100.0% | -99.3% | -79.8% | -77.0% | -39.7% | -10.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AIM
AIM ImmunoTech Inc.
|
BEARISH | $4.24M | - | -% | -% | $0.52 | |
|
JAGX
Jaguar Health, Inc.
|
BEARISH | $4.58M | - | -% | -% | $0.37 | Compare |
|
ISPC
iSpecimen Inc.
|
BEARISH | $3.8M | - | -327.8% | -% | $0.13 | Compare |
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
BEARISH | $4.85M | - | -200.9% | -% | $1.84 | Compare |
|
INBS
Intelligent Bio Solutions Inc.
|
BEARISH | $4.92M | - | -150.2% | -% | $2.46 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-12 | CHEMEROW DAVID I | Director | Stock Award | 25,000 | - |
| 2026-03-12 | EQUELS THOMAS K | Chief Executive Officer | Stock Award | 25,000 | - |
| 2026-02-05 | CHEMEROW DAVID I | Director | Stock Award | 2,800 | $3,444 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning AIM from our newsroom.